The IPO application of Chinese genomics powerhouse BGI’s bid to list on the Chi-Next board of the Shenzhen Stock Exchange has been terminated, as Chinese securities regulator cited incomplete documentation as a reason for inability to proceed with its review.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?